Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD


Clinical Trial Description

- to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD - to evaluate the preliminary efficacy of MA09-hPRE in patients with SMD ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01625559
Study type Interventional
Source CHABiotech CO., Ltd
Contact
Status Completed
Phase Phase 1
Start date September 2012
Completion date April 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02749734 - Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases Phase 1/Phase 2
Completed NCT01345006 - Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy Phase 1/Phase 2
Completed NCT02445612 - Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
Completed NCT02941991 - A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Active, not recruiting NCT03364153 - Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) Phase 2
Completed NCT01469832 - Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) Phase 1/Phase 2